Description
A selective ERK5 inhibitor (Kd = 80 nM); less potently inhibits DCAMKL2, TNK1, and Plk4 (Kds = 190, 890, and 600 nM, respectively); blocks ERK5 autophosphorylation, ERK5-mediated phosphorylation of PML, and PML-dependent activation of p21; inhibits bFGF-induced angiogenesis in a Matrigel™ plug assay in mice; reduces tumor growth in a HeLa mouse xenograft model at 50 mg/kg twice per day; binds BRD4 (Kd = 170 nM for BRD4 bromodomain 1)
Formal name: 2-[[2-ethoxy-4-(4-hydroxy-1-piperidinyl)phenyl]amino]-5,11-dihydro-5,11-dimethyl-6H-pyrimido[4,5-b][1,4]benzodiazepin-6-one
Synonyms:
Molecular weight: 474.6
CAS: 1234480-50-2
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Kinase Inhibitors|Other Serine/Threonine Kinases||Product Type|Biochemicals|Kinase Inhibitors|RAS/RAF/MEK/ERK/MAPK||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Angiogenesis||Research Area|Cancer|Cell Signaling|ERK/MAPK Signaling||Research Area|Epigenetics, Transcription, & Translation|Readers|Bromodomains